Bimekizumab Treatment Safety Profile Confirmed
Three-year pooled data showed no new safety signals for patients using bimekizumab to treat hidradenitis suppurativa.
Updated on Oct. 13, 2026 in Diseases — General
Live Poll
Do you generally trust long-term safety data for new pharmaceutical treatments?
Data from the BE HEARD program indicated that bimekizumab remains safe for patients with moderate to severe hidradenitis suppurativa. The analysis encompassed three years of treatment across 995 participants.
Why it matters
Understanding the long-term safety of biological treatments is essential for managing chronic conditions like hidradenitis suppurativa. These results provide clinicians with critical data regarding potential side effects during extended therapy.
The analysis pooled 995 patients over 2,118.6 patient-years of exposure. Researchers recorded oral candidiasis at a rate of 9.3 per 100 patient-years.
The players
European Academy of Dermatology and Venereology
This is a non-profit association that promotes clinical care, education, and research in the field of dermatology and venereology.
The details
The safety findings, presented in Vienna, combined data from the BE HEARD I, BE HEARD II, and BE HEARD EXT trials. Beyond overall safety, the study noted that bimekizumab treatment effectively reduced the total tunnel count for patients suffering from moderate to severe hidradenitis suppurativa.
Timeline
The data was presented at the EADV Congress 2026, which took place from September 30 through October 3, 2026.
The Big Picture
The BE HEARD clinical trial program established a safety baseline for dermatological treatments that current studies follow. This analysis updates the long-term safety profile of bimekizumab within the framework of the BE HEARD program.
Patients and healthcare providers can use these results to better assess the risks associated with long-term bimekizumab therapy. This data helps clarify expectations regarding common side effects such as oral candidiasis.
The takeaway
These findings support the continued use of bimekizumab as a viable, long-term option for managing severe skin conditions. Patients should consult with their dermatologists to weigh these safety metrics against their specific medical history.
Further reading
Learn more about the latest research in this field in the Diseases — General section.
More information
View the full BE HEARD EXT clinical trial information for additional study details.
Source note: This article includes information reported by Hcplive.
Live Poll
Do you generally trust long-term safety data for new pharmaceutical treatments?
